Display options
Cite
Niolu C, Bianciardi E, Di Lorenzo G, et al. Enhancing adherence, subjective well-being and quality of life in patients with schizophrenia: which role for long-acting risperidone?. Ther Adv Psychopharmacol. 2015;5(5):278-88doi: 10.1177/2045125315596897.
Niolu, C., Bianciardi, E., Di Lorenzo, G., Marchetta, C., Barone, Y., Sterbini, N., Ribolsi, M., Reggiardo, G., & Siracusano, A. (2015). Enhancing adherence, subjective well-being and quality of life in patients with schizophrenia: which role for long-acting risperidone?. Therapeutic advances in psychopharmacology, 5(5), 278-88. https://doi.org/10.1177/2045125315596897
Niolu, Cinzia, et al. "Enhancing adherence, subjective well-being and quality of life in patients with schizophrenia: which role for long-acting risperidone?." Therapeutic advances in psychopharmacology vol. 5,5 (2015): 278-88. doi: https://doi.org/10.1177/2045125315596897
Niolu C, Bianciardi E, Di Lorenzo G, Marchetta C, Barone Y, Sterbini N, Ribolsi M, Reggiardo G, Siracusano A. Enhancing adherence, subjective well-being and quality of life in patients with schizophrenia: which role for long-acting risperidone?. Ther Adv Psychopharmacol. 2015 Oct;5(5):278-88. doi: 10.1177/2045125315596897. PMID: 26557984; PMCID: PMC4622121.
Copy Download .nbib Format: NLM
Share it on

Ther Adv Psychopharmacol. 2015 Oct;5(5):278-88. doi: 10.1177/2045125315596897.

Enhancing adherence, subjective well-being and quality of life in patients with schizophrenia: which role for long-acting risperidone?.

Therapeutic advances in psychopharmacology

Cinzia Niolu, Emanuela Bianciardi, Giorgio Di Lorenzo, Claudia Marchetta, Ylenia Barone, Nicoletta Sterbini, Michele Ribolsi, Giorgio Reggiardo, Alberto Siracusano

Affiliations

  1. Chair of Psychiatry, Department of Systems Medicine, University of Rome 'Tor Vergata', Rome, Italy Psychiatric Clinic, Fondazione Policlinico 'Tor Vergata', Rome, Italy.
  2. Chair of Psychiatry, Department of Systems Medicine, University of Rome 'Tor Vergata', Via Nomentana 1362, 00137 Rome, Italy.
  3. Chair of Psychiatry, Department of Systems Medicine, University of Rome 'Tor Vergata', Rome, Italy.
  4. Biostatistics and Data Management Uni Medi Service, Genoa, Italy.

PMID: 26557984 PMCID: PMC4622121 DOI: 10.1177/2045125315596897

Abstract

AIM: This study evaluated adherence to treatment, quality of life and subjective well-being in patients with psychosis treated with long-acting injectable risperidone. Subjects enrolled were part of a larger study where patients were observed in an adherence to treatment program of the University of Rome Tor Vergata.

MATERIALS AND METHODS: A total of 27 nonadherent patients (21 men, six women; mean age: 36.1 years; range: 23-63 years) were enrolled. Maximum observational period was 30 months.

RESULTS: A total of 12 patients were under treatment for 30 months (44.44%) but only nine had a valid 30-month follow up, while the remaining three patients initially treated at our unit continued long-acting risperidone at their local centre. Reductions of monthly mean values of Scale for the Assessment of Positive Symptoms (SAPS) [repeated measures analysis of variance (rm-ANOVA): p < 0.0001] and Scale for Assessment of Negative Symptoms (SANS) (p < 0.0001), increase of monthly mean values of Subjective Well-Being Under Neuroleptic Treatment Scale (SWN) (p < 0.0001) and Schizophrenia Quality of Life Scale (S-QoL) (p < 0.01) were observed. Significant differences with respect to SAPS baseline values from the sixth month, SANS baseline values from the seventh month, SWN baseline values from the eighth month, S-QoL baseline values from the eighteenth month were shown in post hoc tests. Reduction of SAPS mean values was associated with increase of SWN (p < 0.0001) and S-QoL (p < 0.0001) mean values as demonstrated by correlation analysis. The same inverse correlation was found between reduction of SANS mean values and increases of SWN (p < 0.0001) and S-QoL (p = 0.0001) mean values.

CONCLUSIONS: Long-term treatment with long-acting risperidone may be associated with improvement to adherence to therapy and quality of life. Patients may show improvement in psychopathological symptoms, subjective well-being and quality of life.

Keywords: long-acting antipsychotics; nonadherence; quality of life; risperidone; schizophrenia; subjective well-being

References

  1. Psychiatry Res. 2010 Nov 30;180(1):16-9 - PubMed
  2. Br J Psychiatry Suppl. 2009 Nov;52:S1-4 - PubMed
  3. Expert Opin Drug Saf. 2010 Sep;9(5):683-97 - PubMed
  4. Int Clin Psychopharmacol. 2005 May;20(3):121-30 - PubMed
  5. Schizophr Res. 2003 Sep 1;63(1-2):137-49 - PubMed
  6. Psychiatr Serv. 2012 Jan;63(1):87-90 - PubMed
  7. N Engl J Med. 2011 Mar 3;364(9):842-51 - PubMed
  8. Clin Schizophr Relat Psychoses. 2014 Jan;7(4):199-206 - PubMed
  9. Am J Psychiatry. 2011 Mar;168(3):286-92 - PubMed
  10. Schizophr Res. 2011 Apr;127(1-3):83-92 - PubMed
  11. J Psychopharmacol. 2005 Sep;19(5 Suppl):32-8 - PubMed
  12. Psychiatry Res. 2015 Jan 30;225(1-2):14-30 - PubMed
  13. Schizophr Res. 2011 Aug;130(1-3):176-81 - PubMed
  14. Eur Psychiatry. 2009 Jun;24(5):287-96 - PubMed
  15. J Clin Psychiatry. 2003;64 Suppl 16:14-7 - PubMed
  16. J Clin Psychiatry. 2014;75 Suppl 2:30-3 - PubMed
  17. Eur Neuropsychopharmacol. 2011 May;21(5):370-8 - PubMed
  18. J Clin Psychiatry. 2006 Mar;67(3):453-60 - PubMed
  19. Schizophr Res. 2004 Sep 1;70(1):91-100 - PubMed
  20. Int Clin Psychopharmacol. 1995 Sep;10 Suppl 3:133-8 - PubMed
  21. Aust N Z J Psychiatry. 2013 Jul;47(7):624-30 - PubMed
  22. J Clin Psychiatry. 2013 Oct;74(10):e21 - PubMed
  23. J Clin Psychiatry. 2014 Dec;75(12):e33 - PubMed
  24. Psychiatr Serv. 2004 Sep;55(9):997-1005 - PubMed
  25. Schizophr Res. 2012 Feb;134(2-3):226-31 - PubMed
  26. Acta Psychiatr Scand. 2013 Jan;127(1):23-33 - PubMed
  27. PLoS One. 2012;7(4):e36080 - PubMed
  28. Pharmacopsychiatry. 2006 Jul;39(4):135-41 - PubMed
  29. J Clin Psychiatry. 2003 Oct;64(10):1250-7 - PubMed
  30. J Psychiatr Res. 2012 Aug;46(8):1099-105 - PubMed
  31. J Clin Psychiatry. 2011;72 Suppl 1:9-13 - PubMed
  32. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Jul 1;32(5):1231-5 - PubMed
  33. J Psychopharmacol. 2005 Sep;19(5 Suppl):5-14 - PubMed
  34. J Psychopharmacol. 2015 Aug;29(8):892-7 - PubMed
  35. J Clin Psychopharmacol. 2012 Jun;32(3):323-8 - PubMed
  36. J Clin Psychiatry. 2004 Apr;65(4):531-6 - PubMed
  37. Schizophr Res Treatment. 2012;2012:407171 - PubMed
  38. J Clin Psychiatry. 2003;64 Suppl 16:34-40 - PubMed
  39. Neuropsychiatr Dis Treat. 2010 Dec 22;7:19-26 - PubMed
  40. Int J Neuropsychopharmacol. 2005 Sep;8(3):427-38 - PubMed
  41. BMC Psychiatry. 2012 Mar 26;12:25 - PubMed
  42. BMC Psychiatry. 2011 Aug 26;11:143 - PubMed
  43. Br J Psychiatry. 2010 Dec;197(6):431-2 - PubMed
  44. J Clin Psychiatry. 2002 Oct;63(10):892-909 - PubMed
  45. Psychiatry Res. 2008 Nov 30;161(2):235-47 - PubMed
  46. Ann Gen Psychiatry. 2011 Apr 04;10:10 - PubMed
  47. J Clin Psychiatry. 2004 Aug;65(8):1084-9 - PubMed

Publication Types